Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1999-3-2
pubmed:abstractText
Valproic acid (VPA) is a potent broad spectrum anticonvulsant with demonstrated efficacy in the treatment of Bipolar Affective Disorder, but the biochemical basis for VPA's antimanic or mood-stabilizing actions have not been fully elucidated. It has been demonstrated that VPA, at therapeutically relevant concentrations, increases AP-1 DNA binding activity in cultured cells in vitro. These findings raise the possibility that VPA may produce its mood-stabilizing effects by regulating the expression of subsets of genes via its effects on the AP-1 family of transcription factors. To determine if VPA does, in fact, enhance AP-1 mediated gene expression, the effects of VPA on the expression of a luciferase reporter gene were studied in transiently transfected rat C6 glioma and human SH-SY5Y neuroblastoma cells using the pGL2-control vector. The luciferase gene in the vector is driven by an SV40 promoter which contains well characterized AP-1 sites. VPA produced a greater than doubling of luciferase activity in a time- and concentration-dependent manner in both cell lines. Furthermore, mutations of the AP-1 sites in the SV40 promoter markedly attenuated the VPA-induced increases in luciferase activity. These effects of VPA on AP-1 mediated gene expression are very similar to the effects observed with lithium, and suggest that the temporal regulation of AP-1 mediated gene expression in critical neuronal circuits may play a role in the long-term therapeutic efficacy of these agents.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0169-328X
pubmed:author
pubmed:copyrightInfo
Copyright 1999 Elsevier Science B.V.
pubmed:issnType
Print
pubmed:day
22
pubmed:volume
64
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
52-8
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:9889318-Animals, pubmed-meshheading:9889318-Anticonvulsants, pubmed-meshheading:9889318-Bipolar Disorder, pubmed-meshheading:9889318-DNA-Binding Proteins, pubmed-meshheading:9889318-Gene Expression Regulation, pubmed-meshheading:9889318-Genes, Reporter, pubmed-meshheading:9889318-Glioma, pubmed-meshheading:9889318-Humans, pubmed-meshheading:9889318-Luciferases, pubmed-meshheading:9889318-Molecular Sequence Data, pubmed-meshheading:9889318-Mutation, pubmed-meshheading:9889318-Neuroblastoma, pubmed-meshheading:9889318-Neurons, pubmed-meshheading:9889318-Proto-Oncogene Proteins c-fos, pubmed-meshheading:9889318-Proto-Oncogene Proteins c-jun, pubmed-meshheading:9889318-Rats, pubmed-meshheading:9889318-Sequence Homology, Amino Acid, pubmed-meshheading:9889318-Transcription Factor AP-1, pubmed-meshheading:9889318-Transfection, pubmed-meshheading:9889318-Tumor Cells, Cultured, pubmed-meshheading:9889318-Valproic Acid
pubmed:year
1999
pubmed:articleTitle
Valproate robustly enhances AP-1 mediated gene expression.
pubmed:affiliation
Laboratory of Molecular Pathophysiology, Department of Psychiatry and Behavioral Neurosciences, WSU School of Medicine, 2301 Scott Hall, 540 E. Canfield Avenue, Detroit, MI 48201, USA. gchen@med.wayne.edu
pubmed:publicationType
Journal Article